Caribou Biosciences (CRBU) Latest Stock Analysis Report – Oct 15, 2026, 4:00 PM ET
Updated Oct 15, 2026, 4:00 PM ET
- Closed at $0.47, +1.09% vs the prior close of $0.46.
- Volume 2.88M shares, 1.1x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
CRBU rises 1.1% to $0.47. Closed at $0.47, +1.09% vs the prior close of $0.46. Day range $0.45–$0.48, opened at $0.46.
CRBU daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 15, 2026 — CRBU rises 1.1% to $0.47
- Closed at $0.47, +1.09% vs the prior close of $0.46. Day range $0.45–$0.48, opened at $0.46.
- Volume was 2.88M shares, 1.1x its 50-day average of 2.65M.
- Price is -64.8% vs its 50-day average ($1.32) and -72.5% vs its 200-day average ($1.69).
- 52-week range $0.44–$3.54; today's close sits at 1% of that range, 86.8% below the 52-week high.
Oct 14, 2026 — CRBU dips 2.1% to $0.46
- Closed at $0.46, -2.13% vs the prior close of $0.47. Day range $0.44–$0.48, opened at $0.48.
- Volume was 3.70M shares, 1.4x its 50-day average of 2.60M.
- Price is -65.8% vs its 50-day average ($1.35) and -72.9% vs its 200-day average ($1.70).
- 52-week range $0.44–$3.54; today's close sits at 1% of that range, 87.0% below the 52-week high.
Oct 13, 2026 — CRBU slides 5.4% to $0.47
- Closed at $0.47, -5.43% vs the prior close of $0.50. Day range $0.45–$0.50, opened at $0.48.
- Volume was 4.54M shares, 1.8x its 50-day average of 2.54M.
- Price is -65.6% vs its 50-day average ($1.37) and -72.4% vs its 200-day average ($1.71).
- 52-week range $0.44–$3.54; today's close sits at 1% of that range, 86.7% below the 52-week high.
Oct 12, 2026 — CRBU jumps 8.0% to $0.50 on 2.1x normal volume
- Closed at $0.50, +8.04% vs the prior close of $0.46. Day range $0.44–$0.51, opened at $0.45.
- Volume was 5.26M shares, 2.1x its 50-day average of 2.45M — unusually heavy trading.
- Price is -64.2% vs its 50-day average ($1.39) and -71.0% vs its 200-day average ($1.71).
- 52-week range $0.44–$3.54; today's close sits at 2% of that range, 85.9% below the 52-week high.
Oct 9, 2026 — CRBU slides 4.4% to $0.46, a 52-week low on 4.3x normal volume
- Closed at $0.46, -4.37% vs the prior close of $0.48. Day range $0.44–$0.52, opened at $0.46.
- Volume was 9.74M shares, 4.3x its 50-day average of 2.28M — unusually heavy trading.
- Price is -67.3% vs its 50-day average ($1.41) and -73.2% vs its 200-day average ($1.72).
- 52-week range $0.44–$3.54; today's close sits at 1% of that range, 87.0% below the 52-week high.
- That makes 7 straight losses.
Oct 8, 2026 — CRBU slides 22.0% to $0.48, a 52-week low on 10.1x normal volume
- Closed at $0.48, -22.04% vs the prior close of $0.62. Day range $0.45–$0.60, opened at $0.59.
- Volume was 19.34M shares, 10.1x its 50-day average of 1.92M — unusually heavy trading.
- Price is -66.3% vs its 50-day average ($1.43) and -72.1% vs its 200-day average ($1.72).
- 52-week range $0.45–$3.54; today's close sits at 1% of that range, 86.4% below the 52-week high.
- That makes 6 straight losses.
Oct 7, 2026 — CRBU slides 45.6% to $0.62, a 52-week low on 31.2x normal volume
- Closed at $0.62, -45.64% vs the prior close of $1.13. Day range $0.55–$0.67, opened at $0.64.
- Volume was 37.51M shares, 31.2x its 50-day average of 1.20M — unusually heavy trading.
- Price is -57.4% vs its 50-day average ($1.45) and -64.3% vs its 200-day average ($1.73).
- 52-week range $0.55–$3.54; today's close sits at 2% of that range, 82.5% below the 52-week high.
- That makes 5 straight losses.
Oct 6, 2026 — CRBU slides 4.6% to $1.13, a 52-week low on 5.4x normal volume
- Closed at $1.13, -4.62% vs the prior close of $1.19. Day range $1.13–$1.22, opened at $1.19.
- Volume was 5.94M shares, 5.4x its 50-day average of 1.10M — unusually heavy trading.
- Price is -22.6% vs its 50-day average ($1.47) and -34.6% vs its 200-day average ($1.73).
- 52-week range $1.13–$3.54; today's close sits at 0% of that range, 67.9% below the 52-week high.
- That makes 4 straight losses.
- SEC filings that day: 8-K.
Oct 5, 2026 — CRBU dips 2.5% to $1.19, a 52-week low, 3 down days in a row
- Closed at $1.19, -2.46% vs the prior close of $1.22. Day range $1.17–$1.24, opened at $1.22.
- Volume was 1.55M shares, 1.4x its 50-day average of 1.09M.
- Price is -19.3% vs its 50-day average ($1.48) and -31.5% vs its 200-day average ($1.74).
- 52-week range $1.17–$3.54; today's close sits at 1% of that range, 66.3% below the 52-week high.
- That makes 3 straight losses.
Oct 2, 2026 — CRBU ends flat (+0.0%) to $1.22
- Closed at $1.22, +0.00% vs the prior close of $1.22. Day range $1.22–$1.24, opened at $1.24.
- Volume was 866.50K shares, 0.8x its 50-day average of 1.09M.
- Price is -17.7% vs its 50-day average ($1.48) and -29.9% vs its 200-day average ($1.74).
- 52-week range $1.22–$3.54; today's close sits at 0% of that range, 65.5% below the 52-week high.
CRBU latest news & SEC filings
Every SEC filing by or about CRBU in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 6, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.05 — Costs tied to exiting activities / restructuring.
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
- Item 8.01 — Reported other events the company considers important.
Aug 13, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $1.50M (prior year $2.67M) (-43.8% vs Jun 30, 2025)
- Net income: -$24.28M (prior year -$54.10M) (loss narrowed vs Jun 30, 2025)
- Diluted EPS: -$0.24 (prior year -$0.58) (loss narrowed vs Jun 30, 2025)
Aug 13, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Jul 27, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jun 18, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.07 — Reported shareholder vote results.
Things to know before you trade CRBU
- Last results release: Aug 13, 2026 (8-K Item 2.02). Previous ones: May 7, 2026, Mar 5, 2026, Nov 12, 2025. Based on that rhythm, the next report is likely around Nov 12, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 5.76% (largest 45.6%). That is a volatile stock.
- Liquidity: about 5.04M shares (≈$2.34M) trade per day on average.
- 52-week position: $0.47 vs a range of $0.44–$3.54 (1% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 5 sales; latest: Timothy P Kelly sold 6,228 shares on Feb 25, 2026.
- Latest filings: 8-K Oct 6, 2026; 10-Q Aug 13, 2026; 8-K Aug 13, 2026.
- Share count: 107.21M shares outstanding (Aug 7, 2026), +15.1% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Biological Products, (No Diagnostic Substances).
CRBU market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 15, 2026 | 0.46 | 0.48 | 0.45 | 0.47 | 2.88M |
| Oct 14, 2026 | 0.48 | 0.48 | 0.44 | 0.46 | 3.70M |
| Oct 13, 2026 | 0.48 | 0.50 | 0.45 | 0.47 | 4.54M |
| Oct 12, 2026 | 0.45 | 0.51 | 0.44 | 0.50 | 5.26M |
| Oct 9, 2026 | 0.46 | 0.52 | 0.44 | 0.46 | 9.74M |
| Oct 8, 2026 | 0.59 | 0.60 | 0.45 | 0.48 | 19.34M |
| Oct 7, 2026 | 0.64 | 0.67 | 0.55 | 0.62 | 37.51M |
| Oct 6, 2026 | 1.19 | 1.22 | 1.13 | 1.13 | 5.94M |
| Oct 5, 2026 | 1.22 | 1.24 | 1.17 | 1.19 | 1.55M |
| Oct 2, 2026 | 1.24 | 1.24 | 1.22 | 1.22 | 866.50K |
| Oct 1, 2026 | 1.27 | 1.28 | 1.22 | 1.22 | 686.60K |
| Sep 30, 2026 | 1.28 | 1.28 | 1.25 | 1.27 | 844.80K |
| Sep 29, 2026 | 1.25 | 1.26 | 1.22 | 1.24 | 636.40K |
| Sep 28, 2026 | 1.25 | 1.26 | 1.22 | 1.23 | 818.60K |
| Sep 25, 2026 | 1.25 | 1.27 | 1.22 | 1.24 | 901.30K |
| Sep 24, 2026 | 1.29 | 1.29 | 1.25 | 1.25 | 977.20K |
| Sep 23, 2026 | 1.34 | 1.36 | 1.29 | 1.29 | 699.60K |
| Sep 22, 2026 | 1.32 | 1.36 | 1.31 | 1.34 | 1.22M |
| Sep 21, 2026 | 1.31 | 1.35 | 1.29 | 1.30 | 748.30K |
| Sep 18, 2026 | 1.33 | 1.34 | 1.30 | 1.30 | 1.85M |
About Caribou Biosciences
Caribou Biosciences (CRBU) is listed on the Nasdaq and classified by the SEC under “Biological Products, (No Diagnostic Substances)”. Its business address is in BERKELEY, CA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1619856.
CRBU board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Scott Braunstein | Director | Feb 20, 2026 |
| Andrew Guggenhime | Director | Feb 20, 2026 |
| Rachel E. Haurwitz | President and CEO | Feb 20, 2026 |
| David Lee Johnson | Director | Feb 20, 2026 |
| Dara Richardson-Heron | Director | Feb 20, 2026 |
| Natalie Sacks | Director | Feb 20, 2026 |
| Nancy Whiting | Director | Feb 20, 2026 |
| Ran Zheng | Director | Feb 20, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Tina M. Albertson | Chief Medical Officer | Feb 24, 2026 |
| Rachel E. Haurwitz | President and CEO | Feb 20, 2026 |
| Timothy P Kelly | Chief Technology Officer | Feb 27, 2026 |
| Ruhi Ahmad Khan | Chief Business Officer | Feb 24, 2026 |
| Barbara G Mcclung | Chief Legal Officer | Feb 24, 2026 |
| Sriram Ryali | Chief Financial Officer | Feb 20, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Feb 25, 2026 | Timothy P Kelly | Sale | 6,228 | $1.93 |
| Feb 24, 2026 | Timothy P Kelly | Sale | 3,147 | $1.96 |
| Feb 24, 2026 | Barbara G Mcclung | Sale | 6,938 | $1.96 |
| Feb 24, 2026 | Tina M. Albertson | Sale | 1,066 | $1.96 |
| Feb 24, 2026 | Ruhi Ahmad Khan | Sale | 6,938 | $1.96 |
CRBU financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $11.16M | $-148.12M | -1.59 | $-110.99M |
| Dec 31, 2024 | $9.99M | $-149.10M | -1.65 | $-138.20M |
| Dec 31, 2023 | $34.48M | $-102.07M | -1.38 | $-93.29M |
| Dec 31, 2022 | $13.85M | $-99.42M | -1.64 | $-90.97M |
| Dec 31, 2021 | $9.60M | $-66.92M | -2.11 | $-32.52M |
Latest balance sheet: total assets $142.77M, total liabilities $44.67M, cash $26.19M (as of Jun 30, 2026).
CRBU earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 13, 2026 | 8-K Item 2.02 (results) | $1.61 |
| May 7, 2026 | 8-K Item 2.02 (results) | $1.88 |
| Mar 5, 2026 | 8-K Item 2.02 (results) | $1.71 |
| Nov 12, 2025 | 8-K Item 2.02 (results) | $2.26 |
| Nov 3, 2025 | 8-K Item 2.02 (results) | $2.43 |
| Aug 12, 2025 | 8-K Item 2.02 (results) | $1.79 |
| May 8, 2025 | 8-K Item 2.02 (results) | $0.79 |
| Apr 24, 2025 | 8-K Item 2.02 (results) | $0.87 |
| Mar 10, 2025 | 8-K Item 2.02 (results) | $1.11 |
| Nov 6, 2024 | 8-K Item 2.02 (results) | $2.75 |
| Aug 6, 2024 | 8-K Item 2.02 (results) | — |
| Jul 16, 2024 | 8-K Item 2.02 (results) | — |
Related stocks · Biological Products, (No Diagnostic Substances)
Moderna (MRNA)Amgen (AMGN)Gilead Sciences (GILD)Twist Bioscience (TWST)Argenx Se (ARGX)Biogen (BIIB)Halozyme Therapeutics (HALO)Revolution Medicines (RVMD)Recursion Pharmaceuticals (RXRX)ImmunityBio (IBRX)
Popular today
Micron Technology (MU)Spdr S&P 500 Etf (SPY)Nvidia (NVDA)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Intel (INTC)Apple (AAPL)Microsoft (MSFT)Meta Platforms (META)Broadcom (AVGO)Tesla (TSLA)
More on CRBU
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 15, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.